Literature DB >> 24894456

Infantile myofibromatosis: a series of 28 cases.

Jacob Mashiah1, Smail Hadj-Rabia2, Anne Dompmartin3, Annie Harroche4, Etty Laloum-Grynberg1, Michèle Wolter1, Jean-Claude Amoric1, Dominique Hamel-Teillac1, Stéphane Guero5, Sylvie Fraitag6, Christine Bodemer7.   

Abstract

BACKGROUND: Infantile myofibromatosis (IM) is a rare disorder of fibroblastic/myofibroblastic proliferation in children.
OBJECTIVES: We sought to document common and unusual characteristics of patients with IM.
METHODS: This was a retrospective study of 28 children diagnosed with histopathologically confirmed IM between 1992 and 2012. Epidemiologic, clinical, and treatment data were reviewed.
RESULTS: IM was more frequent in boys (60.8%). Skin lesions were congenital in 64.3% of cases. The solitary form accounted for 50% of cases. Most nodules were painless, arising in cutaneous or subcutaneous tissue. The multicentric form accounted for 39% of cases; the skin, subcutaneous tissue, or muscle was involved in 97.8% of cases, and the bones in 50% of cases. The generalized form had a mortality rate of 33% (one-third of cases). Multicentric and generalized forms regressed spontaneously; severe local complications were observed, and late recurrent nodules developed in a few cases. LIMITATIONS: The retrospective review and the ascertainment of patients (from the departments of obstetrics and pediatrics) may have introduced bias in the analysis of severity of the different forms of IM.
CONCLUSION: The diagnosis of IM must be confirmed histopathologically because the clinical presentation can be misleading. The prognosis is usually good, although local morbidity can occur. The generalized and multicentric forms merit long-term follow-up.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  good prognosis; infantile myofibromatosis; long-term follow-up; pediatrics; systemic complications; tumoral lesions

Mesh:

Year:  2014        PMID: 24894456     DOI: 10.1016/j.jaad.2014.03.035

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  15 in total

1.  Infantile myofibromatosis.

Authors:  Margarita Larralde; Bruno Ferrari; Juan Pablo Martinez; María Angélica Fernández Barbieri; José Higinio Méndez; José Casas
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

Review 2.  PDGF receptor mutations in human diseases.

Authors:  Emilie Guérit; Florence Arts; Guillaume Dachy; Boutaina Boulouadnine; Jean-Baptiste Demoulin
Journal:  Cell Mol Life Sci       Date:  2021-01-15       Impact factor: 9.261

Review 3.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

Review 4.  [Syndroms associated with benign skin tumors].

Authors:  George-Sorin Tiplica; Klaus Fritz; Alexandra Irina Butacu; Loredana Ungureanu; Carmen Maria Sălăvăstru
Journal:  Hautarzt       Date:  2022-01-25       Impact factor: 0.751

Review 5.  [Benign skin neoplasms in children].

Authors:  Carmen Maria Salavastru; Alexandra-Irina Butacu; Klaus Fritz; Seher Eren; George-Sorin Tiplica
Journal:  Hautarzt       Date:  2022-01-14       Impact factor: 0.751

6.  PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.

Authors:  F A Arts; D Chand; C Pecquet; A I Velghe; S Constantinescu; B Hallberg; J-B Demoulin
Journal:  Oncogene       Date:  2015-10-12       Impact factor: 9.867

7.  Diagnosis of infantile myofibromatosis with pseudo-ulcerated plaque using prenatal ultrasound: A case report.

Authors:  Feixue Zhang; Dongfeng Cheng; Mei Wu; Ling Ge; Xiangxing Ma
Journal:  Exp Ther Med       Date:  2014-10-08       Impact factor: 2.447

8.  Infantile Myofibroma Presenting as a Large Ulcerative Nodule in a Newborn.

Authors:  Farooq Shahzad; Ava G Chappell; Chad A Purnell; Monica Aldulescu; Sarah Chamlin
Journal:  Case Rep Pediatr       Date:  2019-09-17

9.  Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib.

Authors:  Mohammed Hassan; Erin Butler; Raphael Wilson; Angshumoy Roy; Yanbin Zheng; Priscilla Liem; Dinesh Rakheja; Dean Pavlick; Lauren L Young; Mark Rosenzweig; Rachel Erlich; Siraj M Ali; Patrick J Leavey; D Williams Parsons; Stephen X Skapek; Theodore W Laetsch
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-10-23

10.  Aggressive infantile myofibromatosis with intestinal involvement.

Authors:  Tristan Römer; Norbert Wagner; Till Braunschweig; Robert Meyer; Miriam Elbracht; Udo Kontny; Olga Moser
Journal:  Mol Cell Pediatr       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.